The evolution of rectal cancer treatment: the journey to total neoadjuvant therapy and organ preservation

被引：30

作者：

Affleck, Arthur ^{[1
]}

Koprowski, Marina Affi ^{[1
]}

Nabavizadeh, Nima ^{[2
]}

Tsikitis, Vassiliki Liana ^{[3
]}

机构：

[1] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA

[2] Oregon Hlth & Sci Univ, Dept Radiat Med, Portland, OR 97201 USA

[3] Oregon Hlth & Sci Univ, Dept Surg, Div Gastrointestinal Surg, Portland, OR 97201 USA

来源：

ANNALS OF GASTROENTEROLOGY | 2022年 / 35卷 / 03期

关键词：

Rectal cancer; total neoadjuvant therapy; total mesorectal excision; complete clinical response; TOTAL MESORECTAL EXCISION; PHASE-III TRIAL; PREOPERATIVE RADIOTHERAPY; OPEN-LABEL; POSTOPERATIVE CHEMORADIOTHERAPY; ADJUVANT CHEMOTHERAPY; FOLLOW-UP; MULTICENTER; SURVIVAL; SURGERY;

D O I：

10.20524/aog.2022.0712

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

There has been a staggering increase in the incidence of rectal cancer, drawing our attention to early detection and optimization of its medical and surgical treatment. With this review we highlight all the major trials that revolutionized rectal cancer management and improved oncologic outcomes. We present the origins of the trimodal therapy and the studies that supported the sequence of treatment. We describe the evolution in surgical management with total mesorectal excision as the standard of care, and we review the most impactful short-course versus long-course radiation therapy trials. Today, the current standard of care for non-metastatic locally advanced rectal cancer includes preoperative chemoradiation with either induction or consolidation chemotherapy, total mesorectal excision and adjuvant therapy. We discuss the advent of the "watch and wait" strategy for patients who have a complete clinical response after total neoadjuvant treatment, as well as possible future directions in the treatment of locoregional disease.

引用

页码：226 / 233

页数：8

共 47 条

[11] Long-course preoperative chemoradiation versus 5 x 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study [J].

Cisel, B. ;

Pietrzak, L. ;

Michalski, W. ;

Wyrwicz, L. ;

Rutkowski, A. ;

Kosakowska, E. ;

Cencelewicz, A. ;

Spalek, M. ;

Polkowski, W. ;

Jankiewicz, M. ;

Stylinski, R. ;

Bebenek, M. ;

Kapturkiewicz, B. ;

Maciejczyk, A. ;

Sadowski, J. ;

Zygulska, J. ;

Zegarski, W. ;

Jankowski, M. ;

Las-Jankowska, M. ;

Toczko, Z. ;

Zelazowska-Omiotek, U. ;

Kepka, L. ;

Socha, J. ;

Wasilewska-Tesluk, E. ;

Markiewicz, W. ;

Kladny, J. ;

Majewski, A. ;

Kapuscinski, W. ;

Suwinski, R. ;

Bujko, K. .

ANNALS OF ONCOLOGY, 2019, 30 (08) :1298-1303

[12] Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23) : a multicentre, randomised, open-label, phase 3 trial [J].

Conroy, Thierry ;

Bosset, Jean-Francois ;

Etienne, Pierre-Luc ;

Rio, Emmanuel ;

Francois, Eric ;

Mesgouez-Nebout, Nathalie ;

Vendrely, Veronique ;

Artignan, Xavier ;

Bouche, Olivier ;

Gargot, Dany ;

Boige, Valerie ;

Bonichon-Lamichhane, Nathalie ;

Louvet, Christophe ;

Morand, Clotilde ;

de la Fouchardiere, Christelle ;

Lamfichekh, Najib ;

Juzyna, Beata ;

Jouffroy-Zeller, Claire ;

Rullier, Eric ;

Marchal, Frederic ;

Gourgou, Sophie ;

Castan, Florence ;

Borg, Christophe .

LANCET ONCOLOGY, 2021, 22 (05) :702-715

[13]

Conroy T, 2020, J CLIN ONCOL, V38

[14] Marked improvements in survival of patients with rectal cancer in the Netherlands following changes in therapy, 1989-2006 [J].

Elferink, M. A. G. ;

van Steenbergen, L. N. ;

Krijnen, P. ;

Lemmens, V. E. P. P. ;

Rutten, H. J. ;

Marijnen, C. A. M. ;

Nagtegaal, I. D. ;

Karim-Kos, H. E. ;

de Vries, E. ;

Siesling, S. .

EUROPEAN JOURNAL OF CANCER, 2010, 46 (08) :1421-1429

[15] Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial [J].

Erlandsson, Johan ;

Holm, Torbjorn ;

Pettersson, David ;

Berglund, Ake ;

Cedermark, Bjorn ;

Radu, Calin ;

Johansson, Hemming ;

Machado, Mikael ;

Hjern, Fredrik ;

Hallbook, Olof ;

Syk, Ingvar ;

Glimelius, Bengt ;

Martling, Anna .

LANCET ONCOLOGY, 2017, 18 (03) :336-346

[16] Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods [J].

Ferlay, J. ;

Colombet, M. ;

Soerjomataram, I. ;

Mathers, C. ;

Parkin, D. M. ;

Pineros, M. ;

Znaor, A. ;

Bray, F. .

INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (08) :1941-1953

[17] Tumor Regression Grading After Preoperative Chemoradiotherapy as a Prognostic Factor and Individual-Level Surrogate for Disease-Free Survival in Rectal Cancer [J].

Fokas, Emmanouil ;

Stroebel, Philipp ;

Fietkau, Rainer ;

Ghadimi, Michael ;

Liersch, Torsten ;

Grabenbauer, Gerhard G. ;

Hartmann, Arndt ;

Kaufmann, Marco ;

Sauer, Rolf ;

Graeven, Ullrich ;

Hoffmanns, Hans ;

Raab, Hans-Rudolf ;

Hothorn, Torsten ;

Wittekind, Christian ;

Roedel, Claus .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (12)

[18] Swedish rectal cancer trial: Long lasting benefits from radiotherapy on survival and local recurrence rate [J].

Folkesson, J ;

Birgisson, H ;

Pahlman, L ;

Cedermark, B ;

Glimelius, B ;

Gunnarsson, U .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) :5644-5650

[19] Planned organ preservation for early T2-3 rectal adenocarcinoma: A French, multicentre study [J].

Gerard, Jean-Pierre ;

Barbet, Nicolas ;

Gal, Jocelyn ;

Dejean, Catherine ;

Evesque, Ludovic ;

Doyen, Jerome ;

Coquard, Regis ;

Gugenheim, Jean ;

Benizri, Emmanuel ;

Schiappa, Renaud ;

Baudin, Guillaume ;

Benezery, Karene ;

Francois, Eric .

EUROPEAN JOURNAL OF CANCER, 2019, 108 :1-16

[20] Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious? [J].

Glynne-Jones, R ;

Grainger, J ;

Harrison, M ;

Ostler, P ;

Makris, A .

BRITISH JOURNAL OF CANCER, 2006, 94 (03) :363-371

← 1 2 3 4 5 →